Clinical trials · Philadelphia, PA
Refractory Malignant Solid Neoplasm clinical trials in Philadelphia
We’re tracking 6 recruiting refractory malignant solid neoplasm studies with a site in or near Philadelphia — including Phase 1 and Phase 1/Phase 2 studies, each written for real people, not researchers.
Recruiting studies near Philadelphia
- NCT04104776RecruitingPhase 1/Phase 2
Test drug tulmimetostat for advanced cancers and lymphomas
This early-phase study tests tulmimetostat (DZR123) to shrink or control advanced solid tumors and certain lymphomas, and it may also test a combination in some prostate cancer groups. If you qualify, you’ll receive the study drug and be monitored closely, including blood tests and a request for tumor tissue to look for biomarkers.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06586957RecruitingPhase 1
Study of NKT3964 for advanced solid tumors
This trial is testing an experimental oral drug called NKT3964 for people with advanced solid tumors that have stopped responding to standard treatments. The drug works by blocking a protein called CDK2, which some cancers need to grow.
Philadelphia, PennsylvaniaAges 18 years+ - NCT06941272RecruitingPhase 1/Phase 2
Study of patritumab deruxtecan for children with hard-to-treat solid tumors
This trial tests a new drug, patritumab deruxtecan, in children and adolescents whose rhabdomyosarcoma or hepatoblastoma has returned or not responded to at least one prior treatment. The goal is to see if the drug can shrink tumors or stop them from growing.
Philadelphia, PennsylvaniaAges 1 month–17 years - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Philadelphia, PennsylvaniaAges 1–30 - NCT07630974RecruitingPhase 1/Phase 2
New Cancer Drug for Children With Hard-to-Treat Solid Tumors
This trial tests a new drug called ifinatamab deruxtecan in children whose solid tumors (cancers that form lumps, excluding brain tumors) have come back or stopped responding to previous treatments. The drug is designed to target and kill cancer cells while potentially causing fewer side effects than standard chemotherapy.
Philadelphia, PennsylvaniaAges 1 month–17 years - NCT02402244Recruiting
Caring registry study for children and young people with cancer
This study keeps a careful record of children, teens, and young adults with cancer (and some related growths) and may follow them over time. It helps researchers better track outcomes and future contact so care can improve.
Philadelphia, PennsylvaniaAges Up to 25 years
Hear when a new Refractory Malignant Solid Neoplasm trial opens near Philadelphia, PA
We’ll email you when one opens near Philadelphia, PA — at most once a week, no account needed, unsubscribe anytime.
Refractory Malignant Solid Neoplasm trials in other cities
Where these studies are running near Philadelphia
Institutions with a site for the recruiting refractory malignant solid neoplasm studies listed above.
- Children's Hospital of Philadelphia · 4 studies
- Alfred I. duPont Hospital for Children
- Drexel University
- Lehigh Valley Hospital - Muhlenberg
- Lehigh Valley Hospital-Cedar Crest
- Saint Christopher's Hospital for Children
- Thomas Jefferson University Hospital
- University of Pennsylvania
What taking part in a refractory malignant solid neoplasm study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting refractory malignant solid neoplasm studies in Pennsylvania.
Common questions
- Are there refractory malignant solid neoplasm clinical trials near Philadelphia?
- Yes. We're currently tracking 6 recruiting refractory malignant solid neoplasm studies with a site near Philadelphia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a refractory malignant solid neoplasm study near Philadelphia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Philadelphia to take part?
- Not necessarily. These studies have a site near Philadelphia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a refractory malignant solid neoplasm trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New refractory malignant solid neoplasm studies open near Philadelphia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.